JeffreyW.TaubMD

Pediatric Hematology & Oncology • Detroit, MI

Division Chief of Oncology, Professor of Pediatrics, Children's Hosp of Michigan, Wayne State Univer

Join to view full profile

Dr. Taub is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Taub's full profile

Already have an account?

Office
3901 Beaubien St
Detroit, MI 48201
Phone+1 313-966-0660

Fax+1 313-745-5420
Is this information wrong?

Education & Training

Children's Hospital of MichiganFellowship, Pediatric Hematology/Oncology, 1994
DMC Children's Hospital of Michigan1991
University of Western OntarioMD, Medicine, 1983 - 1987
University of Western OntarioClass of 1987

Certifications & Licensure

MI State Medical License 1988 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FAAP) American Academy of Pediatrics
Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01
Completed
Phase 3
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder Start of enrollment: 2006 Mar 01
Withdrawn
Phase 3
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2008 Aug 04
Completed
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET) Start of enrollment: 2011 Feb 01
Unknown status
Not Applicable
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission Start of enrollment: 2012 Feb 21
Active, not recruiting
Phase 3
Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial Start of enrollment: 2012 Feb 01
Completed
Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder Start of enrollment: 2012 Feb 01
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Start of enrollment: 2017 Mar 29
Active, not recruiting
Phase 2, Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia.
Yongwei Su, Jenna L Carter, Xinyu Li, Yu Fukuda, Ashley Gray, John Lynch, Holly Edwards, Jun Ma, Patrick Schreiner, Lisa Polin, Juiwanna Kushner, Sijana H Dzinic, Stev...> ;Cancer Research. 2024 Apr 1
Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
Jianlei Zhao, Shuangshuang Wu, Deying Wang, Holly Edwards, Jenna Thibodeau, Seongho Kim, Paul Stemmer, Guan Wang, Jingji Jin, Süreyya Savasan, Jeffrey W Taub, Yubin Ge> ;Biochemical Pharmacology. 2024 Feb 17
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
Hurrish, K., Su, Y., Patel, S., Ramage, C., Zhao, J., Temby, B., Carter, J., Edwards, H., Buck, S., Wiley, S., Hüttemann, M., Polin, L., Kushner, J., Dzinic, S., White...> ;Biochemical Pharmacology. 2024 Feb 1
2 citations
Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
Jenna L Carter, Yongwei Su, Xinan Qiao, Jianlei Zhao, Guan Wang, Mackenzie Howard, Holly Edwards, Xun Bao, Jing Li, Maik Hüttemann, Jay Yang, Jeffrey W Taub, Yubin Ge> ;Biochemical Pharmacology. 2023 Oct 1
Smaller Hippocampal Volume Is Associated With Reduced Posttraumatic Stress Symptoms in Children With Cancer and Survivors Following a Brief Novel Martial Arts-Based In...
Julia M Evanski, Allesandra Iadipaolo, Samantha L Ely, Clara G Zundel, Leah C Gowatch, Amanpreet Bhogal, Zazai Owens, Cindy Cohen, Elimelech Goldberg, Martin H Bluth, ...> ;Archives of Clinical Neuropsychology. 2024 Feb 19
1 citations
Curing childhood cancer the "Natural" Way: Nature as the source of chemotherapy agents.
Eman T Al-Antary, Avanti Gupte, Jenna Carter, Mirna Kaafarani, Mackenzie Howard, Holly Edwards, Yubin Ge, Jeffrey W Taub> ;Biochemical Pharmacology. 2023 Jul 1
Pediatric acute myeloid leukemia with breast chloromas.
Maria S Gallardo, Richard Joyrich, Jeffrey W Taub> ;Ejhaem. 2023 May 1
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.
Katie H Hurrish, Yongwei Su, Shraddha Patel, Cassandra L Ramage, Jenna L Carter, Holly Edwards, Steven A Buck, Sandra E Wiley, Maik Hüttemann, Lisa Polin, Juiwanna Kus...> ;Research Square. 2023 Apr 28
7 citations
Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
Katie Hege Hurrish, Xinan Qiao, Xinyu Li, Yongwei Su, Jenna Carter, Jun Ma, Hasini A Kalpage, Maik Hüttemann, Holly Edwards, Guan Wang, Seongho Kim, Alan Dombkowski, X...> ;Biochemical Pharmacology. 2022 Nov 1
1 citations
Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of-Mutated Acute Myeloid Leukemia.
Shuangshuang Wu, Holly Edwards, Deying Wang, Shuang Liu, Xinan Qiao, Jenna Carter, Yue Wang, Jeffrey W Taub, Guan Wang, Yubin Ge> ;Cells. 2022 Sep 3
8 citations
c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.
Shuang Liu, Xinan Qiao, Shuangshuang Wu, Yuqinq Gai, Yongwei Su, Holly Edwards, Yue Wang, Hai Lin, Jeffrey W Taub, Guan Wang, Yubin Ge> ;Apoptosis. 2022 Dec 1
1 citations
Meditation reduces brain activity in the default mode network in children with active cancer and survivors.
Aneesh Hehr, Allesandra S Iadipaolo, Austin Morales, Cindy Cohen, Jeffrey W Taub, Felicity W K Harper, Elimelech Goldberg, Martin H Bluth, Christine A Rabinak, Hilary ...> ;Pediatric Blood & Cancer. 2022 Oct 1
10 citations
"FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.
Tristan E Knight, Holly Edwards, Soheil Meshinchi, Jeffrey W Taub, Yubin Ge> ;Cancers. 2022 Jul 13
4 citations
The paradox of Myeloid Leukemia associated with Down syndrome.
Avanti Gupte, Eman T Al-Antary, Holly Edwards, Yaddanapudi Ravindranath, Yubin Ge, Jeffrey W Taub> ;Biochemical Pharmacology. 2022 Jul 1
2 citations
When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3-ITD AML
Tristan Knight, Yubin Ge, Jeffrey W. Taub, Johann Hitzler, Joerg Krueger> ;Pediatric Blood & Cancer. 2021 Aug 6
12 citations
High-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531.
Johann Hitzler, Todd A. Alonzo, Robert B. Gerbing, Amy Beckman, Betsy A. Hirsch, Susana C. Raimondi, Karen M. Chisholm, Shelton A Viola, Lisa Eidenschink Brodersen, Mi...> ;Blood. 2021 Jul 28
MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition
Tristan Knight, Holly Edwards, Jeffrey W. Taub, Yubin Ge> ;Ebiomedicine. 2021 Jul 16
3 citations
Slow Transcription of the 99a/let-7c/125b-2 Cluster Results in Differential MiRNA Expression and Promotes Melanoma Phenotypic Plasticity.
Danna Sheinboim, Shivang Parikh, Roma Parikh, Amitai Menuchin, Guy Shapira, Oxana Kapitansky, Nadav Elkoshi, Shmuel Ruppo, Lital Shaham, Tamar Golan, Sharona Elgavish,...> ;The Journal of Investigative Dermatology. 2021 Dec 1
22 citations
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
Xinan Qiao, Jun Ma, Tristan Knight, Yongwei Su, Holly Edwards, Lisa Polin, Jing Li, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jian Wang, Hai Lin, Yue Wang, Li...> ;Blood Cancer Journal. 2021 Jun 7
Unusual clinical behavior of a very late retinoblastoma relapse in a patient with a germline RB mutation.
Yogindra Persaud, Marjilla Seddiq, Yi-Mi Wu, Dan R. Robinson, Janet Poulik, Deniz Altinok, John D. Roarty, Rajen Mody, Jeffrey W. Taub> ;Pediatric Blood & Cancer. 2021 May 18
4 citations
Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
Manisha Gadgeel, Batool Al‐Qanber, Steven Buck, Jeffrey W. Taub, Yaddanapudi Ravindranath, Süreyya Savaşan> ;Annals of Hematology. 2021 Apr 23
4 citations
Martial Arts-Based Therapy Reduces Pain and Distress Among Children with Chronic Health Conditions and Their Siblings
Hilary A. Marusak, Allesandra S. Iadipaolo, Cindy Cohen, Elimelech Goldberg, Jeffrey W. Taub, Felicity W. K. Harper, Martin H. Bluth, Christine A. Rabinak> ;Journal of Pain Research. 2020 Dec 29
6 citations
Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second "Hit" in Leukemogenesis.
Yogindra Persaud, Mark Shamoun, Meera Chitlur, Kyle J Des Rosier, Jeffrey W. Taub> ;Journal of Pediatric Hematology/oncology. 2021 Nov 1
82 citations
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter, Katie Hege, Jay Yang, Hasini A. Kalpage, Yongwei Su, Holly Edwards, Maik Hüttemann, Jeffrey W. Taub, Yubin Ge> ;Signal Transduction and Targeted Therapy. 2020 Dec 18
12 citations
Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia.
Seth E. Karol, Todd M. Cooper, Paul E. Mead, Kristine R. Crews, John C. Panetta, Thomas B. Alexander, Jeffrey W. Taub, Norman J. Lacayo, Kenneth Heym, Dennis John Kuo,...> ;Cancer. 2020 Nov 1
Join now to see all

Abstracts/Posters

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML
Jeffrey W. Taub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction
Jeffrey W. Taub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML
Jeffrey W. Taub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Biomedical Engineer and Quality Assurance Expert, Jeffrey P. Taub, Joins NDA Partners as Expert ConsultantMay 27th, 2020
‘Those on the Front Lines of Cancer’ to Air on PBSOctober 3rd, 2019
A High-Throughput Screen Indicates Gemcitabine and JAK Inhibitors May Be Useful for Treating Pediatric AMLMay 16th, 2019
Join now to see all

Grant Support

Molecular And Pharmacologic Correletes Of Acute Myeloid Leukemia In DOWN SyndromeNational Cancer Institute2007–2011
Cystathionine B Synthase And ARA C Therapy For LeukemiaNational Cancer Institute2001–2005